ReviewDrug design, development and therapy2024
Clinical Application and Research Progress of Remimazolam for Pediatric Patients.
Review in Drug design, development and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Effective doses of remimazolam for sedation in paediatric magnetic resonance imaging following dexmedetomidine premedication: a dose-finding study.BMC anesthesiology · 2026Trial
- Remimazolam versus Sevoflurane for Paediatric Circumcision: A Randomised Controlled Trial Evaluating Emergence Delirium.Drug design, development and therapy · 2026Trial
- Remimazolam in pediatric sedation and anesthesia: current perspectives and clinical considerations.Journal of intensive care · 2026Review
- Emerging Sedation Strategies in Pediatric Emergency Care: Pharmacological Advances and Clinical Applications.Cureus · 2026Review
- Random forest-based prediction of early postoperative pain after pelvic organ prolapse surgery under standardized remimazolam anesthesia.BMC anesthesiology · 2026Observational
- An evaluation of the relationship between BIS and MOAA/S during remimazolam-sufentanil induction: a prospective observational study.Frontiers in medicine · 2026Article
- Research Progress on the Clinical Application of Remimazolam Outside the Operating Room: A Review of Pharmacological Characteristics, Clinical Effects, and Safety.Clinical pharmacology : advances and applications · 2025Review
- Effective doses of remimazolam and esketamine combined with remifentanil for endotracheal intubation without muscle relaxants in pediatric patients.Frontiers in pharmacology · 2025Article
- Remimazolam and Its Place in the Current Landscape of Procedural Sedation and General Anesthesia.Journal of clinical medicine · 2024Review
- Remimazolam in General Anesthesia: A Comprehensive Review of Its Applications and Clinical Efficacy.Drug design, development and therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remimazolam is a novel ultrashort-acting benzodiazepine that allosterically modulates γ-aminobutyric acid type A (GABAA) receptors to exert sedative effects. Remimazolam has the properties of controllable sedation, rapid onset, and a short duration of action, along with minor depression of circulation and respiration. Remimazolam has been approved for clinical use since 2020 in Japan, and it has been applied for procedural sedation, general anesthesia induction and maintenance, and sedation in ICU patients, and has been proven to be safe and effective. Currently, no consensus has been reached on the clinical application of remimazolam in pediatric patients. This review introduces the clinical research progress and limitations of remimazolam in recent years, aiming to supply scientific guidance and a theoretical reference for the application of remimazolam in pediatric anaesthesia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.